Key points are not available for this paper at this time.
Although resistance to arsenic trioxide in patients with acute promyelocytic leukemia is very rare, mutations in PML at the site of arsenic binding appears to be the main mechanism of resistance.
Zhu et al. (Wed,) studied this question.